Atlas Trials

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Clinical trial NCT05213767 · UNKNOWN

Trial details

NCT number
NCT05213767
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Tumors
Start date
2022-02-01
Primary completion
2023-05-01
Enrollment
190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.